Anti-Tripeptidyl Peptidase-2 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the aminoterminal end of human Tripeptidyl-peptidase 2 (TPP2, UniProt P29144); validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential
UniProt
P29144
Size
100ug
Cat. #
RP2Tripeptidyl Peptidase2

In stock

SKU
RP-Tripeptidyl Peptidase2

Options

As low as: $130.00

Target Overview

Tripeptidyl-peptidase 2 (TPP2; UniProt P29144; gene: TPP2) is a high-molecular-weight cytosolic serine peptidase that processively releases N-terminal tripeptides from oligopeptides generated by the 26S proteasome. Classified under EC 3.4.14.10, the enzyme functions as a downstream component of the ubiquitin-proteasome proteolytic cascade, extending the degradative capacity of the proteasome toward shorter peptide intermediates that would otherwise accumulate in the cytoplasm. TPP2 has a deduced sequence length of 1,249 amino acids and self-assembles into a large spindle-shaped complex with a native molecular weight in the megadalton range, distinguishing it structurally from other cytosolic aminopeptidases. TPP2 is expressed broadly across mammalian tissues and localises predominantly to the cytoplasm, where it contributes directly to intracellular amino acid homeostasis by feeding free amino acids back into the cellular pool following proteasomal degradation. In addition to its aminopeptidase activity, the enzyme has been reported to stimulate adipogenesis, implicating it in metabolic regulation beyond simple protein turnover. Researchers use TPP2 as a study target in the context of antigen processing and MHC class I peptide presentation, where proteasome-independent trimming of peptide precursors is relevant to immunological studies. The protein has also attracted attention in investigations of immune competence, autoimmunity, and disorders arising from defects in intracellular proteolysis. The immunogen for this antibody corresponds to the aminoterminal region of the human TPP2 protein, providing detection of the full-length form under denaturing and native tissue conditions.

Background

**Role in the Ubiquitin-Proteasome Pathway** Tripeptidyl-peptidase 2 occupies a functionally important position downstream of the 26S proteasome in the ubiquitin-dependent protein degradation pathway. Whereas the proteasome generates oligopeptides typically 3–25 residues in length, TPP2 acts on the shorter products, sequentially liberating N-terminal tripeptides to drive complete substrate resolution. This activity has been characterised as essential for maintaining intracellular amino acid homeostasis, ensuring that cytoplasmic peptide fragments do not accumulate to levels that could interfere with normal cellular signalling or protein synthesis. The enzyme's large spindle-shaped oligomeric architecture is thought to confer processivity, allowing it to handle the continuous peptide flux produced during active proteasomal degradation. **Antigen Processing and Immune Function** Beyond bulk proteolysis, TPP2 has been studied for its contribution to MHC class I antigen presentation. Certain viral and self-derived epitopes require trimming of proteasome-generated precursors before loading onto class I molecules, and TPP2 has been identified as one of the cytosolic peptidases capable of performing this trimming step. Consistent with this role, TPP2 deficiency has been investigated in the context of primary immunodeficiency; rare loss-of-function variants in TPP2 have been identified in patients with autoimmune and immune dysregulation phenotypes, and the gene has appeared in sequencing studies of rare variants within inborn-error-of-immunity gene sets in cohorts with severe infectious disease (Barros de Oliveira Sá MV et al., Hum Immunol, 2026; PMID: 42190421). **Metabolic and Broader Research Contexts** TPP2 has also been studied as a research target in metabolic contexts, given evidence that it stimulates adipogenesis. Gene-signature studies examining immune infiltration and endocrine-related conditions have included TPP2 among differentially expressed transcripts, reflecting its broader expression across metabolically active tissues. Triple Point Biologics has been producing validated proteinase and inhibitor antibodies since 1994; this rabbit polyclonal, raised against the aminoterminal end of TPP2, is validated for Western blot, with potential cross-reactivity in additional species.

References

  1. Yang P et al. Identification and functional analysis of two novel tpp genes in Bacillus thuringiensis HSY91. Pestic Biochem Physiol. 2026. doi:10.1016/j.pestbp.2026.107157. PMID: 42264755.
  2. Barros de Oliveira Sá MV et al. Rare variants in inborn errors of immunity genes in young adults with severe COVID-19: Insights from a Brazilian cohort. Hum Immunol. 2026. doi:10.1016/j.humimm.2026.111764. PMID: 42190421.
  3. He J et al. Gene signatures associated with exosomes as diagnostic markers of postpartum depression and their role in immune infiltration. Front Endocrinol (Lausanne). 2025. doi:10.3389/fendo.2025.1542327. PMID: 40747300.
  4. Mir R et al. A rare likely pathogenic HLA-DRB1 variant with compromised immunity in severe COVID-19 patient and in-hospital mortality. Per Med. 2025. doi:10.1080/17410541.2025.2538424. PMID: 40704829.
  5. Yuan YT et al. Filamentous chemokine CCL5 structure and the functional aspects. Sci Rep. 2025. doi:10.1038/s41598-025-98114-9. PMID: 40253490.

Additional Specifications

Size 100 µg
Gene Symbol TPP2
UniProt ID P29144
Host Species Rabbit
Species Reactivity Validated- Human
Potential
Pack Size 100ug
Immunogen (Aminoterminal end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 2-52.
Immunogen (Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 9-508.
Immunogen (carboxyterminal from the catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 468-508.
Immunogen (Carboxyterminal end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 1199-1249.

Frequently Asked Questions

What molecular weight band should I expect for TPP2 on a Western blot?

TPP2 has a deduced sequence of 1,249 amino acids, corresponding to a predicted monomer molecular weight of approximately 138 kDa. On reducing SDS-PAGE, you should observe a prominent band in the 135–140 kDa range. Be aware that TPP2 natively assembles into a large spindle-shaped oligomeric complex exceeding 1 MDa in the cytosol, but under denaturing Western blot conditions the antibody detects the dissociated monomer. Some lysates may show minor higher-molecular-weight species if incomplete denaturation occurs; boiling samples thoroughly in SDS loading buffer resolves this.

What dilution should I start with for Western blot with this TPP2 antibody?

We recommend starting at 1:1000 dilution in blocking buffer for Western blot, based on validation in human cell lysates. This polyclonal antibody is supplied at 100 µg per vial. Depending on your expression level and detection system sensitivity, you may optimize between 1:500 and 1:2000. TPP2 is a relatively abundant cytosolic peptidase in many cell types, so signal intensity is usually robust at 1:1000. Always include a no-primary control and consider titrating if background appears elevated or signal is weak in your specific lysate.

Is this TPP2 antibody validated for immunohistochemistry or immunofluorescence?

Triple Point Biologics antibodies are validated for Western blot and immunohistochemistry (IHC) as part of our standard workflow. While we have not independently validated this particular TPP2 polyclonal for immunofluorescence (IF), the rabbit host and epitope accessibility often translate well to IF applications. TPP2 localizes predominantly to the cytoplasm, so you should observe diffuse cytoplasmic staining. Start with a 1:100–1:200 dilution for IHC or IF, and always include isotype or pre-immune serum controls. Antigen retrieval may improve IHC signal; citrate buffer at pH 6.0 is a reasonable starting point.

Does this antibody cross-react with mouse or rat TPP2?

This antibody is validated for human TPP2. Cross-reactivity with mouse and rat is predicted based on high sequence conservation across mammalian orthologs—human and mouse TPP2 share approximately 85–90 percent amino acid identity. However, we have not experimentally confirmed detection in mouse or rat lysates. If you plan to work with non-human samples, we recommend running a positive control human lysate in parallel and verifying that the band you observe at approximately 138 kDa in rodent samples matches the expected size and tissue expression pattern reported in the literature.

What positive control cell line or tissue should I use for TPP2 Western blots?

TPP2 is broadly expressed across mammalian tissues, with particularly high levels in metabolically active cells. HeLa, HEK293, and Jurkat whole-cell lysates serve as reliable positive controls for Western blot; all three typically yield strong signal at the expected 138 kDa band. If working with tissue, liver, kidney, and spleen lysates show robust TPP2 expression. Load 20–30 µg total protein per lane as a starting point. Because TPP2 is cytosolic and abundant, you should not require enrichment or subcellular fractionation for detection in standard whole-cell extracts.

Are there known isoforms or splice variants of TPP2 I should be aware of?

The primary TPP2 transcript encodes the full-length 1,249-amino-acid protein, and this is the predominant isoform detected in most tissues. Minor splice variants have been reported in transcript databases, but their expression at the protein level is either very low or unconfirmed. You should expect a single major band at approximately 138 kDa on Western blot. If you observe additional bands, consider the possibility of proteolytic cleavage, post-translational modification, or non-specific binding. Running a peptide competition assay or siRNA knockdown can help confirm specificity of any unexpected bands.

How should I store this TPP2 antibody and what is the expected shelf life?

Store the antibody at –20°C in small aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. The polyclonal format is supplied in a stabilized buffer; shelf life is typically 12–24 months when stored properly. Avoid prolonged exposure to room temperature. For day-to-day use, you may keep a working aliquot at 4°C for up to one month. Do not add sodium azide if you plan to use the antibody for applications involving HRP-conjugated secondary reagents, as azide inhibits peroxidase activity. Centrifuge briefly before use if you observe any precipitate.

What sample preparation considerations are important for detecting TPP2 by Western blot?

TPP2 is a cytosolic serine peptidase, so standard RIPA or NP-40 lysis buffers work well. Include protease inhibitors—particularly serine protease inhibitors such as PMSF or AEBSF—to prevent autolysis or degradation during lysis, though TPP2 itself is relatively stable. Avoid prolonged incubation at room temperature after lysis. Boil samples in reducing SDS sample buffer for five minutes to ensure complete denaturation and monomer dissociation, as TPP2 forms large native oligomers. Load 20–30 µg total protein per lane and transfer to PVDF or nitrocellulose; standard transfer conditions are sufficient for this 138 kDa target.

Validation imagery coming soon

Western blot validation figures for RP-Tripeptidyl Peptidase2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →